Idexx Laboratories Inc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +0.15%.
Did IDXX Beat Earnings? Q3 2025 Results
IDEXX Laboratories posted a standout third quarter, with earnings per share of $3.40 beating the $3.14 consensus estimate by 8.29%, extending the company's streak of beating EPS expectations to four consecutive quarters. Revenue of $1.11 billion grew 13.3% year over year and came in 3.16% ahead of the Street's $1.07 billion forecast, underpinned by exceptional commercial momentum in the Companion Animal Group, where over 1,700 placements of the new inVue Dx cellular analyzer drove capital instrument revenues sharply higher and signaled accelerating adoption of IDEXX's in-house imaging platform. Gross margin expanded 70 basis points to 61.8%, while operating margin reached 32.1%, reflecting favorable volume leverage and pricing gains. Free cash flow nearly doubled to $371.23 million. Encouraged by the broad-based strength, management raised full-year 2025 revenue guidance to $4.27 billion to $4.30 billion and lifted EPS guidance to $12.81 to $13.01, citing stronger CAG recurring revenue trends, higher inVue Dx placements, and operational execution as the key drivers of the improved outlook.
- Strong IDEXX VetLab consumables growth driven by testing utilization gains and 10% premium instrument installed base expansion
- CAG Diagnostics recurring revenue outpaced sector growth with 11% reported growth (10% organic)
- Over 1,700 IDEXX inVue Dx placements drove 74% CAG Diagnostics capital instrument revenue growth
- International CAG Diagnostics recurring revenue grew 18% reported (14% organic)
- U.S. growth aided by increased diagnostic frequency and easing clinical visit pressures
- Reference lab productivity initiatives and volume gains supported gross margin expansion
- Net price realization helped offset inflationary impacts
“IDEXX made exceptional progress on our innovation-driven growth strategy with strong execution and global customer adoption. Building on the successful launch of IDEXX Cancer Dxâ„¢, new Catalyst specialty tests for Pancreatic Lipase and Cortisol, and the transformative impact of IDEXX inVue Dx, we are delivering powerful new diagnostic capabilities. These solutions elevate clinical insights, streamline workflows, and create meaningful value for veterinary teams. The enthusiastic response — as reflected in our strong growth profile — highlights the trust our customers place in IDEXX.”
IDEXX Laboratories CEO, on the earnings call
Forward Guidance & Outlook
IDEXX raised its full-year 2025 revenue guidance to $4,270–$4,300 million (9.6%–10.3% reported growth; 8.8%–9.5% organic growth), an increase of ~$43 million at midpoint from prior guidance, reflecting stronger CAG Diagnostics recurring revenue performance and higher IDEXX inVue Dx instrument placements and revenues. Full-year EPS outlook was increased to $12.81–$13.01 (20%–22% reported growth; 12%–14% comparable growth), a $0.33 increase at midpoint versus prior guidance, driven by $0.22 from operational performance, $0.04 from lower effective tax rate, and ~$0.07 from updated interest expense, share count, and FX estimates. Full-year operating margin is now projected at 31.6%–31.8%, representing 260–280 basis points of reported expansion. CAG Diagnostics recurring revenue growth is projected at 8.3%–9.0% reported (7.5%–8.2% organic). Capital expenditures are projected at approximately $140 million, with free cash flow conversion of 95%–100% of net income. The effective tax rate is expected at approximately 20.8%.
IDXX YoY Financials
IDXX Revenue by Segment
IDXX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.